Compare American Well Corp (AMWL) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Boston Scientific Corporation — how do they compare? American Well Corp trades at $12.73 (market cap $220.94M), while Boston Scientific Corporation trades at $51.47 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 335.8× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| AMWL | BSX | |
|---|---|---|
Market Cap | $220.94M | $74.19B |
Sector | Health | Health |
52-Week High | $13.58 | $108.14 |
52-Week Low | $3.78 | $42.63 |
Enterprise Value | $27.98M | $86.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $12.93, down 4.79% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q2 2026 revenue of $52 million, beating estimates, and continues to narrow losses, targeting cash-flow breakeven by Q4 2026. Recent news includes a key executive joining Amazon's healthcare unit, highlighting strategic relevance.
Outlook hinges on achieving profitability targets amid declining revenues. Opportunities include operational efficiency gains and high-profile partnerships, but risks persist from sustained net losses and competitive pressures. Analyst consensus is cautious with 67% hold ratings.
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
